|Day Low/High||2.36 / 2.48|
|52 Wk Low/High||0.24 / 0.65|
RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Advanced Bladder Cancer Resistant to Gemcitabine who had failed on Multiple Prior Treatments
Patent Protection Extended until 2034
Patent Protection for RX-3117 Extended until 2036
Evidence of Prolonged Progression Free Survival in Pancreatic Cancer Patients Treated with RX-3117 and for Whom Three or More Prior Therapies had been Ineffective
RX-3117 is Currently in a Phase Ib/IIa Clinical Trial in Patients with Metastatic Pancreatic Cancer
Presents Clinical Data for Novel Targeted Cancer Therapeutics, RX-3117, Supinoxin™ and Archexin® at Prominent Oncology Conferences
Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.